BIO-RAD LABORATORIES-A (BIO) Stock Analyst Ratings
USA - NYSE:BIO - US0905722072 - Common Stock
330.42 USD
-5.7 (-1.7%)
330.42 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 78% to BIO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 317.22. This target is -3.99% below the current price.
BIO was analyzed by 10 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about BIO.
In the previous month the buy percentage consensus was at a similar level.
BIO was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-01 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-06-09 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-02 | Citigroup | Maintains | Buy -> Buy |
| 2025-04-17 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-12 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-01-14 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-12-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-10-31 | Citigroup | Maintains | Buy -> Buy |
| 2024-10-01 | Citigroup | Upgrade | Neutral -> Buy |
| 2024-08-27 | Wells Fargo | Initiate | Equal-Weight |
| 2024-08-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-08-02 | Citigroup | Maintains | Neutral -> Neutral |
| 2024-05-08 | UBS | Maintains | Buy -> Buy |
| 2024-04-03 | Citigroup | Downgrade | Buy -> Neutral |
| 2024-02-16 | UBS | Maintains | Buy -> Buy |
| 2024-02-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-12-07 | UBS | Initiate | Buy |
| 2023-08-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023-08-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-08-04 | Credit Suisse | Maintains | Outperform -> Outperform |
| 2023-06-16 | Wells Fargo | Initiate | Overweight |
| 2023-05-08 | RBC Capital | Maintains | Outperform |
| 2023-05-08 | Citigroup | Maintains | Buy |
| 2023-05-05 | Credit Suisse | Maintains | Outperform |
| 2023-02-17 | RBC Capital | Maintains | Outperform |
BIO-RAD LABORATORIES-A / BIO FAQ
Can you provide the average price target for BIO-RAD LABORATORIES-A stock?
10 analysts have analysed BIO and the average price target is 317.22 USD. This implies a price decrease of -3.99% is expected in the next year compared to the current price of 330.42.
What is the consensus rating for BIO stock?
The consensus rating for BIO-RAD LABORATORIES-A (BIO) is 78 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for BIO stock?
The number of analysts covering BIO-RAD LABORATORIES-A (BIO) is 10.